NKGen Biotech Inc. Common Stock (NKGN)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in NKGen Biotech Inc. Common Stock, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

NKGen Biotech Inc. Common Stock (NKGN) has returned 40.00% so far this year and -61.11% over the past 12 months.

Based on dividend-adjusted daily data since Jul 13, 2021, NKGN's average daily return is +1.15%, while the average monthly return is -1.58%.

Historically, 54% of months were positive and 46% were negative. The best month was Mar 2024 with a return of +137.1%, while the worst month was Oct 2025 at -81.8%. The longest winning streak lasted 12 consecutive months, and the longest losing streak was 5 months.

On a daily basis, NKGN closed higher 32% of trading days. The best single day was Oct 13, 2025 with a return of +400.0%, while the worst single day was Oct 3, 2025 at -99.8%.

NKGen Biotech Inc. Common Stock has an annualized alpha of 1525.89%, beta of 0.82, and R² of 0.00 versus S&P 500 Index. Calculated based on daily prices since July 14, 2021.

• This stock participated in 172.49% of S&P 500 Index downside but only -119.00% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.00 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

NKGN ranks 56 for risk / return — on par with similar stocks. You're getting a typical balance of risk and reward. Not a standout, but not a red flag either — a reasonable choice if other factors align with your goals.

The table below present risk-adjusted performance metrics for NKGen Biotech Inc. Common Stock (NKGN) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the NKGen Biotech Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the NKGen Biotech Inc. Common Stock was 100.00%, occurring on Oct 3, 2025. The portfolio has not yet recovered.

The current NKGen Biotech Inc. Common Stock drawdown is 99.38%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of NKGen Biotech Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how NKGen Biotech Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.